The primary outcome measure of the ASPIRE trial is overall survival, which refers to the length of time patients live after starting treatment. Secondary outcomes include progression-free survival, which measures the time during which a patient's cancer does not worsen, and response rate, which indicates the proportion of patients whose cancer shrinks or disappears. Additionally, the trial assesses quality of life and the incidence of adverse effects associated with the treatments.
